(loo-TEE-shee-um … vy-PIH-voh-tide teh-TRAK-seh-tan)
This page contains brief information about lutetium Lu 177 vipivotide tetraxetan and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Lutetium Lu 177 vipivotide tetraxetan is approved to treat:
- Prostate cancer that overproduces the PSMA protein and did not respond to treatments that lower testosterone levels. It is used in adults whose cancer has spread to other parts of the body and has been treated with an androgen receptor blocker and taxane-based chemotherapy.
More About Lutetium Lu 177 Vipivotide Tetraxetan
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Lutetium Lu 177 Vipivotide Tetraxetan – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Clinical Trials Accepting Patients
Find Clinical Trials for Lutetium Lu 177 Vipivotide Tetraxetan – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
